Nutriband Inc. (NTRB)
NASDAQ (CM) NASDAQ (CM) Primary 
XFRA Summary
NTRB Chart
Nutriband Receives China Patent Notice of Allowance for Its Aversa(TM) Abuse Deterrent Transdermal Technology
Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for the patent application covering its Platform AVERSA™ abuse deterrent transdermal technology Nutriband abuse-deterrent transdermal technology consists of a proprietary aversive agent coating that employs taste aversion to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products AVERSA Fentanyl has the potential to be the world's first and only abuse-deterrent opioid patch ORLANDO, FL / ACCESSWIRE / September 24, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received a Notice of Allowance from the Chinese National Intellectual Property Administration (CNIPA) for patent application entitled, "Abuse and Misuse Deterrent Transdermal Systems," which protects its AVERSA™ abuse deterrent transdermal technology. The Aversa™ abuse deterrent technology is now covered by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, Mexico, Canada, Australia, and China.
Nutriband Inc. Authorizes $1M Share Buyback Program
ORLANDO, FL / ACCESSWIRE / September 16, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced a share repurchase program to buy back up to $1,000,000 of its common stock. As of September 16, 2024, the Company had 11,106,185 shares of common stock outstanding.
Nutriband Inc. Quarterly Report Highlights Strong Cash Position, and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025
ORLANDO, FL / ACCESSWIRE / September 4, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has reported its financial results for the second quarter ended July 31, 2024. The Company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, AVERSA™ Fentanyl, with an NDA submission targeted for the first half of 2025.
Nutriband Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 3 | $23.61 | $9.03 | -$14.58 | -61.75% |
 Alisha Arvold Christopher J. Hasenberg, Inc | 200 | $1,226 | $602 | -$624 | -50.9% |
| SC Stacey Cole Haven Private LLC | 11,366 | $53,533.56 | $34,666.3 | -$18,867.26 | -35.24% |
Nutriband Inc. (NTRB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Nutriband Inc. ever had a stock split?
Nutriband Inc. Profile
| Biotechnology Industry | Healthcare Sector | Gareth Sheridan CEO | NASDAQ (CM) Exchange | 67092M208 CUSIP |
| US Country | 13 Employees | - Last Dividend | 12 Aug 2022 Last Split | 30 Nov 2017 IPO Date |
Overview
Nutriband Inc. is a pharmaceutical company specialized in the development of transdermal (through the skin) drug delivery systems. The company focuses on creating products that offer alternatives to traditional methods of medication administration, including pills and injections, with an emphasis on abuse-deterrent formulations. Founded in 2016 and based in Orlando, Florida, Nutriband Inc. aims to address critical areas of need within pain management, chronic diseases, and reproductive health through its innovative transdermal technologies. By pursuing partnerships and licensing agreements, such as with Rambam Med-Tech Ltd. and Kindeva Drug Delivery, L.P., Nutriband is expanding its developmental capabilities and product portfolio to include devices and treatments designed for safety, efficacy, and convenience.
Products and Services
- AVERSA fentanyl
This lead product is an abuse-deterrent fentanyl transdermal system intended for managing chronic pain that requires constant, around-the-clock opioid therapy. By employing a transdermal method, AVERSA fentanyl aims to provide a reliable, extended-release option that mitigates abuse potential, offering a safer alternative for clinicians and patients alike.
- AVERSA buprenorphine and AVERSA methylphenidate
Expanding its portfolio focused on abuse deterrent solutions, Nutriband is developing transdermal systems for buprenorphine and methylphenidate. These products are geared towards improving treatment options for opioid dependence recovery and attention deficit hyperactivity disorder (ADHD), respectively, through innovative transdermal delivery technologies.
- Exenatide for type 2 diabetes
Nutriband is exploring the development of a transdermal system for the administration of exenatide, a medication used in the treatment of type 2 diabetes. This effort is aimed at enhancing patient compliance and ease of use compared to traditional injection methods, potentially improving outcomes for those managing this chronic condition.
- Follicle stimulating hormone for infertility
The company is also working on a transdermal delivery system for follicle stimulating hormone (FSH), a treatment used in assisting reproductive technologies for infertility. By introducing a non-invasive method for administering FSH, Nutriband hopes to reduce the discomfort and inconvenience associated with injections, thus improving the treatment experience for patients.
- RAMBAM Closed System Transfer Devices
In collaboration with Rambam Med-Tech Ltd., Nutriband is developing the RAMBAM Closed System Transfer Devices. These devices are designed to safely transfer medication from one container to another, reducing the risk of exposure to hazardous drugs, thereby enhancing safety protocols in medical facilities.
- AVERSAL Fentanyl with Kindeva Drug Delivery, L.P.
Through a partnership with Kindeva Drug Delivery, L.P., Nutriband is working on AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. This collaboration seeks to further the development of safe, effective, abuse-deterrent opioid therapy options for chronic pain management.
